【摘要】 肾性贫血是导致慢性肾脏病(CKD)疾病进展的的独立危险因素。新型治疗肾性贫血药物罗沙司他利用机体对低氧的自然反应，激活低氧诱导信号通路，同时调控内源性促红细胞生成素(EPO)生成并改善铁代谢，有效纠正血红蛋白水平，综合调节红细胞生成。更多还原

【Abstract】 Renal anemia is an independent risk factor for progression of chronic kidney disease(CKD).Roxadustat, a novel medicine for renal anemia, utilizes the body’s native response to hypoxia for activating the hypoxia-induced signaling pathway, regulating endogenous erythropoietin(EPO) production and improving iron metabolism, so effectively corrects hemoglobin level and comprehensively regulates erythropoiesis.更多还原